Kymera Therapeutics completes enrollment in Phase 2b BROADEN2 trial of KT-621 for atopic dermatitis

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

KYMR

0.00
  • Kymera Therapeutics completed enrollment in the Phase 2b BROADEN2 trial of KT-621 in moderate-to-severe atopic dermatitis.
  • Topline results have not been presented yet; the readout is now expected by year-end 2026, about six months earlier than prior timing.
  • The study is designed to show whether the oral STAT6 degrader can improve disease severity and patient well-being while remaining tolerable.
  • Phase 3 atopic dermatitis trials are planned to start by mid-2027, subject to regulatory discussions.
  • A separate Phase 2b asthma trial of KT-621 remains ongoing, with results expected in late 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.